Published in Blood Weekly, September 30th, 1996
The finding is among the results of the second Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (Gusto IIb) study published in the September 12, 1996, issue of the New England Journal of Medicine.
The 12,142-patient study compared heparin, the intravenous anticoagulant routinely used today, with hirudin, a genetically engineered compound that is not yet commercially available. Hirudin is a protein derived from leech saliva, the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.